Petrov Ye. Ye., Burmak Yu. H., Ivanytska T. A., Trybrat T. A., Savchuk T. A.

SOME PECULIARITIES OF SEASONAL DEVIATIONS IN INDICATORS OF LIPID PEROXIDATION AND ANTIOXIDANT PROTECTION IN PATIENTS WITH COMPENSATED CHRONIC COR PULMONALE OF BRONCHO-PULMONARY GENESIS AND IN THE CONDITIONS OF ITS COMORBIDITY WITH STABLE CORONARY HEART DISEASE

---

Show/Download

About the author:

Petrov Ye. Ye., Burmak Yu. H., Ivanytska T. A., Trybrat T. A., Savchuk T. A.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

It is known that chronic obstructive pulmonary disease (COPD) and cardiovascular diseases have common pathophysiological mechanisms that are closely related to oxidative stress. In order to research the peculiarities of the state of lipid peroxidation (LPO), the antioxidant defense (AOD) system and their seasonal deviations in patients with compensated chronic cor pulmonale (CCP) of broncho-pulmonary genesis in conditions of comorbidity with stable coronary heart disease (CHD), a study and analysis of LPO indicators (diene conjugates, malondialdehyde), the AOD system (erythrocytes peroxide hemolysis test, superoxide dismutase, catalase, ceruloplasmin) in 52 patients with COPD and compensated CCP, among whom 32 patients had comorbid stable CHD (the main group), were carried out; 20 patients with isolated pathology (COPD with compensated CCP) formed the comparative group. The research was carried out during summer-autumn and winter-spring seasons. It was established that in patients of the comparative group the activation of LPO processes is observed, while the intensity of their seasonal fluctuations is minimal. Patients of the main group are characterized by a higher activity of LPO processes, which is combined with a decrease in the activity of the enzyme link of the AOD system, and an increase in the intensity of LPO with signs of depletion of the functional activity of key enzymes of the AOD system is observed during winter-spring period of the year; this result implies the need to use a differentiated approach in the complex treatment of these patients to optimize the antioxidant status.

Tags:

Bibliography:

1. Feshchenko YuI, Ostrovsʹkyy MM, Makoyda IYa. Modyfikatsiya perebihu khronichnoho obstruktyvnoho zakhvoryuvannya lehenʹ: mif chy nahalʹni realiyi sʹohodennya? Ukr Pulmon Zh. 2022;30(1):47-51. DOI: 10.31215/2306-4927-2022-30-1-47-5. [in Ukrainian].
2. Ilashchuk TO, Mykytyuk OP, Chobanu YaV. Osoblyvosti poyednanoho perebihu khronichnoho obstruktyvnoho zakhvoryuvannya lehenʹ ta khronichnoyi ishemichnoyi khvoroby sertsya (ohlyad literatury). Klinichna ta eksperymentalʹna patolohiya. 2021;2(76):96-104. DOI: 10.24061/1727-4338.XX.2.76.2021.14. [in Ukrainian].
3. Global initiative for chronic obstructive lung disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD. 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT ver1.0wms.pdf.
4. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1-16. DOI: 10.1177/1753465817750524.
5. Trinkmann F, Saur J, Borggrefe M, Akin I. Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) - Current Considerations for Clinical Practice. J Clin Med. 2019;8(1):69. DOI: 10.3390/jcm8010069.
6. Brassington K, Selemidis S, Bozinovski S, Vlahos R. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease. Clin Sci. 2019 Apr 12;133(7):885-904. DOI: 10.1042/CS20180316.
7. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-88. DOI: 10.1016/S0140-6736(18)32203-7.
8. Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013 Oct;144(4):1163- 78. DOI: 10.1378/chest.12-2847.
9. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015 Aug;3(8):631-9. DOI: 10.1016/S2213-2600(15)00241-6.
10. Voynarovsʹka HP, Asanov EO. Ishemichna khvoroba sertsya ta khronichne obstruktyvne zakhvoryuvannya lehenʹ: aktualʹna problema komorbidnosti u vnutrishniy medytsyni. Scientifjc Journal «ScienceRise: Medical Science». 2020;3(36):20-4. DOI: 10.15587/2519-4798.2020.203968. [in Ukrainian].
11. Axson EL, Ragutheeswaran K, Sundaram V, Bloom CI, Bottle A, Cowie MR, et al. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res. 2020 Feb 14;21(1):54. DOI: 10.1186/s12931-020-1312-7.
12. Voskresensky ON, Zhutaev IA, Bobyrev VN, Bezugly YuV. The antioxidant system, ontogenesis and ageing. Voprosy Meditsinskoj Khimii. 1982;28(1):14-27.
13. Baraboy VA, Brekhman II, Golotin VG, Kudryashov YuB. Perekisnoye okisleniye i stress. SPb.: Nauka; 1992. 148 s.
14. Cristóvão C, Cristóvão L, Nogueira F, Bicho M. Evaluation of the oxidant and antioxidant balance in the pathogenesis of chronic obstructive pulmonary disease. Rev Port Pneumol. 2013;19(2):70-5. DOI: 10.1016/j.rppneu.2012.09.002.
15. Önder E, Duman BA, Kenanoğlu O, Çetinkaya M, Gül MF, Işık FB, et al. The lipid peroxidation in Chronic Obstructive Pulmonary Disease. Thorac Res Pract. 2019;20:364.
16. Gianazza E, Brioschi M, Martinez Fernandez A, Casalnuovo F, Altomare A, Aldini G, et al. Lipid Peroxidation in Atherosclerotic Cardiovascular Diseases. Antioxid Redox Signal. 2021 Jan 1;34(1):49-98. DOI: 10.1089/ars.2019.7955.
17. Dubois-Deruy E, Peugnet V, Turkieh A, Pinet F. Oxidative Stress in Cardiovascular Diseases. Antioxidants (Basel). 2020 Sep 14;9(9):864. DOI: 10.3390/antiox9090864.
18. Miklós Z, Horváth I. The Role of Oxidative Stress and Antioxidants in Cardiovascular Comorbidities in COPD. Antioxidants. 2023;12(6):1196. DOI: https://doi.org/10.3390/antiox12061196.
19. Nakaz MOZ Ukrayiny vid 27 chervnya 2013 №555. Khronichne obstruktyvne zakhvoryuvannya leheni. Adaptovana klinichna nastanova, zasnovana na dokazakh. Kyyiv: MOZ Ukrayiny; 2013. Dostupno: . [in Ukrainian].
20. Feshchenko YuI, Gavrysyuk VK, Dzyublyk OYa, Mostovoy YuM, Pertseva TO, Polyanska MO, ta in. Adaptovana klinichna nastanova: khronichne obstruktyvne zakhvoryuvannya lehen. Ukr Pulmon Zh. 2020;3:5-36. DOI: 10.31215/2306-4927-2020-109-3-5-36. [in Ukrainian].
21. Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023 Apr 1;61(4):2300239. DOI: 10.1183/13993003.00239-2023.
22. Gavrysyuk VK. Khronycheskoye legochnoye serdtse. Praktychna angiologiya. 2008;4(15). Dostupno: https://angiology.com.ua/ua/archive/ 2008/4%2815%29/article-155/hronicheskoe-legochnoe-serdce.
23. Nakaz MOZ Ukrayiny №2857 vid 23.12.2021 Pro zatverdzhennya Unifikovanoho klinichnoho protokolu pervynnoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomohy «Stabilʹna ishemichna khvoroba sertsya». Kyyiv: MOZ Ukrayiny; 2021. Dostupno: https://zakon.rada.gov.ua/rada/show/v2857282-21#Text. [in Ukrainian].
24. Vladimirov YuA, Archakov AI. Perekisnoye okisleniye lipidov v biologicheskikh membranakh. M.: Nauka; 1972. 252 s.
25. Jager FC. Determination of vitamin E requirement in rats by means of spontaneous haemolysis in vitro. Nutr Dieta Eur Rev Nutr Diet. 1968;10(3):215-23. DOI: 10.1159/000175223.
26. Kolb VG, Kamyshnikov VS. Spravochnik po klinicheskoy khimii. Minsk: Belarus’; 1982. 366 s.
27. Brusov OS, Gerasimov AM, Panchenko LF. Vliyaniye prirodnykh ingibitorov radikal’nykh reaktsiy na avtookisleniye adrenalina. Byuleten’ eksperimental’noy biologii i meditsiny.1976;1:33-5.
28. Papaporfyriou A, Bartziokas K, Gompelmann D, Idzko M, Fouka E, Zaneli S, et al. Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy. Life (Basel). 2023 May 31;13(6):1299. DOI: 10.3390/life13061299.
29. Zaremba YeH, Fedechko MY, Makar OR, Kopchak LM, Izhytsʹka NV. Pryntsypy diahnostyky ta likuvannya ishemichnoyi khvoroby sertsya u poyednanni z khronichnym obstruktyvnym zakhvoryuvannyam lehenʹ u praktytsi simeynoho likarya. Semeynaya medytsyna. 2016;6:98- 101. [in Ukrainian].
30. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003 Mar 25;107(11):1514-9. DOI: 10.1161/01.cir.0000056767.69054.b3.
31. Petrov YeYe, Burmak YuH, Treumova SI, Ivanytsʹka TA, Savchuk TA. Osoblyvosti sezonnykh zmin stanu perekysnoho okysnennya lipidiv ta antyoksydantnoho zakhystu u khvorykh na kompensovane khronichne leheneve sertse bronkho-lehenevoho henezu ta v umovakh yoho komorbidnosti z hipertonichnoyu khvoroboyu. Materialy nauk.-prakt. konf. z mizhnarodnoyu uchastyu Suchasni aspekty vilʹnoradykalʹnoyi patolohiyi v eksperymentalʹniy ta klinichniy medytsyni; 2020 Trav 7-8; Poltava. Poltava: PDMU; 2020. s. 20-2. [in Ukrainian].
32. Wang W, Kang PM. Oxidative Stress and Antioxidant Treatments in Cardiovascular Diseases. Antioxidants (Basel). 2020 Dec 17;9(12):1292. DOI: 10.3390/antiox9121292.
33. Barnes PJ. Oxidative Stress in Chronic Obstructive Pulmonary Disease. Antioxidants (Basel). 2022;11(5):965. DOI: 10.3390/antiox11050965.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 2, 173, 241-245 pages, index UDC 616.12-005.4/31:616.23/.24:611.018-06-07

DOI:

10.29254/2077-4214-2024-2-173-241-245